Vivos Therapeutics Inc (VVOS) Q4 2025 Earnings Call Highlights: Revenue Growth Amid Strategic ... [Yahoo! Finance]
Vivos Therapeutics, Inc. (VVOS)
Company Research
Source: Yahoo! Finance
Sleep Testing Services Revenue: Increased by approximately $4.8 million. Revenue from Treatment at SCN Locations: Increased by approximately $2.2 million. Legacy VIP Dentists Revenue Decline: Decreased by approximately $1.4 million. Service Revenue Decline: Decreased by approximately $2 million in VIP enrollment revenue. Gross Profit: $10.5 million, a 17% increase from 2024. Gross Margin: Remained constant at 60% for 2025 and 2024. Operating Expenses: $30.4 million for 2025, up from $20.2 million in 2024. General and Administrative Expenses: Increased by $9.8 million to $27.7 million. Sales and Marketing Expenses: Decreased by $300,000 to $1.4 million. Net Loss: Increased to $21.2 million for 2025. Net Cash Used in Operating Activities: Approximately $15.3 million for 2025. Total Liabilities: Approximately $26.7 million as of December 31, 2025. Cash and Cash Equivalents: Approximately $2 million as of December 31, 2025. Warning! GuruFocus has detected 7 Warn
Show less
Read more
Impact Snapshot
Event Time:
VVOS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VVOS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VVOS alerts
High impacting Vivos Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
VVOS
News
- Vivos Therapeutics (VVOS) had its price target lowered by Ascendiant Capital Markets from $5.50 to $3.00. They now have a "buy" rating on the stock.MarketBeat
- Vivos Therapeutics (VVOS) had its "sell (e+)" rating reaffirmed by <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Vivos Therapeutics (VVOS) had its price target lowered by HC Wainwright from $7.00 to $2.50. They now have a "buy" rating on the stock.MarketBeat
- Vivos Therapeutics Schedules Release of Full Year 2025 Financial Results and Conference Call [Yahoo! Finance]Yahoo! Finance
- Vivos Therapeutics Reports Full Year 2025 Financial Results [Yahoo! Finance]Yahoo! Finance
VVOS
Earnings
- 11/19/25 - Beat
VVOS
Analyst Actions
- 4/22/26 - Ascendiant Capital
VVOS
Sec Filings
- 4/22/26 - Form 8-K
- 4/15/26 - Form 8-K
- 4/15/26 - Form 10-K
- VVOS's page on the SEC website